Readystate Asset Management LP Sells 5,558 Shares of Jazz Pharmaceuticals PLC $JAZZ

Readystate Asset Management LP trimmed its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 31.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,251 shares of the specialty pharmaceutical company’s stock after selling 5,558 shares during the quarter. Readystate Asset Management LP’s holdings in Jazz Pharmaceuticals were worth $1,615,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of JAZZ. Farther Finance Advisors LLC grew its position in Jazz Pharmaceuticals by 754.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after acquiring an additional 234 shares during the last quarter. Hantz Financial Services Inc. boosted its stake in Jazz Pharmaceuticals by 471.4% in the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 297 shares in the last quarter. Quent Capital LLC bought a new stake in shares of Jazz Pharmaceuticals during the third quarter worth $44,000. Geneos Wealth Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 137 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Jazz Pharmaceuticals by 30.7% in the third quarter. GAMMA Investing LLC now owns 655 shares of the specialty pharmaceutical company’s stock valued at $86,000 after buying an additional 154 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Activity

In other Jazz Pharmaceuticals news, Director Heather Ann Mcsharry sold 3,415 shares of the company’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $177.78, for a total value of $607,118.70. Following the completion of the sale, the director owned 20,449 shares of the company’s stock, valued at approximately $3,635,423.22. This represents a 14.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total transaction of $379,363.38. Following the transaction, the senior vice president directly owned 19,508 shares in the company, valued at approximately $3,306,801.08. This represents a 10.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 87,813 shares of company stock worth $15,564,549 over the last quarter. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Up 1.0%

Shares of Jazz Pharmaceuticals stock opened at $167.98 on Wednesday. The business has a fifty day simple moving average of $167.66 and a 200 day simple moving average of $148.16. The stock has a market cap of $10.21 billion, a PE ratio of -27.67, a price-to-earnings-growth ratio of 0.89 and a beta of 0.26. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $182.99.

Analyst Ratings Changes

JAZZ has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. TD Cowen reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Thursday, January 29th. JPMorgan Chase & Co. dropped their price objective on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research report on Monday, October 27th. Wells Fargo & Company upped their price objective on Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Finally, Piper Sandler reissued an “overweight” rating and issued a $219.00 target price (up from $147.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 10th. Fourteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $205.67.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.